1 / 9

Elbasvir-Grazoprevir in HCV Treatment-naïve PWID on Opiate Agonist Therapy: Study Features and Results

This study explores the use of Elbasvir-Grazoprevir in the treatment of hepatitis C virus (HCV) genotype 1, 4, or 6 in PWID on opiate agonist therapy. The study features, results, drug dosing, treatment efficacy, and safety are discussed.

ajames
Download Presentation

Elbasvir-Grazoprevir in HCV Treatment-naïve PWID on Opiate Agonist Therapy: Study Features and Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 Injection Drug Use TreatmentNaïve Elbasvir-Grazoprevirin HCV GT 1,4, or 6 in PWID* on Opiate Agonist TherapyC-EDGE CO-STAR *PWID = Persons Who Inject Drugs Dore G, et al. AALSD. 2015; Abstract 40.

  2. Elbasvir-Grazoprevirin HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Study Features Source: Dore G, et al. AALSD. 2015; Abstract 40.

  3. Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Study Features 0 12 16 40 24 28 Week Treatment-naïve GT 1, 4 or 6 (N=301) Elbasvir-Grazoprevir- N=201 SVR12 Elbasvir-Grazoprevir- Placebo N=100 SVR12 Drug DosingGrazoprevir-elbasvir (100/50 mg): fixed dose combination; one pill once daily Source: Dore G, et al. AALSD. 2015; Abstract 40.

  4. Elbasvir-Grazoprevirin HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Results in Immediate Treatment Group C-EDGE CO-STAR: SVR12 Results with Full Analysis Set 184/201 144/154 28/30 11/12 1/5 *Includes one subject with mixed infection (GT 1a and 1b) who achieved SVR12 Source: Dore G, et al. AALSD. 2015; Abstract 40.

  5. Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Results in Immediate Treatment Group C-EDGE CO-STAR: SVR12 Results with Modified Full Analysis Set^ 189/198 147/153 28/29 11/11 3/5 ^Excludes patients who discontinued trial for non-treatment related reasons*Includes one subject with mixed infection (GT 1a and 1b) who achieved SVR12 Source: Dore G, et al. AALSD. 2015; Abstract 40.

  6. Elbasvir-Grazoprevirin HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Results C-EDGE CO-STAR: SVR12 Results with Modified Full Analysis Set^ 151/158 38/40 83/85 106/113 83/85 106/113 Cirrhosis HCV RNA IU/ml Drug Screen ^Excludes patients who discontinued trial for non-treatment related reasons Source: Dore G, et al. AALSD. 2015; Abstract 40.

  7. Elbasvir-Grazoprevirin HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Results C-EDGE CO-STAR: Adherence Overall Source: Dore G, et al. AALSD. 2015; Abstract 40.

  8. Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Safety Source: Dore G, et al. AALSD. 2015; Abstract 40.

  9. Elbasvir-Grazoprevir in HCV GT 1, 4, or 6 in PWID on Opiate Agonist TherapyC-EDGE CO-STAR: Conclusions Source: Dore G, et al. AALSD. 2015; Abstract 40.

More Related